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Abstract  1 
Objective 2 
Uncontrolled rapid release of drugs can reduce their therapeutic efficacy and cause undesirable toxicity; 3 
however, controlled release from reservoir materials helps overcome this issue. The aims of this study were to 4 
determine the release profiles of ketoprofen and spironolactone from a pH-responsive self-assembling DPA-5 
MPC-DPA triblock copolymer gel, and elucidate underlying physiochemical properties. 6 
Methods 7 
Drug release profiles from DPA50-MPC250-DPA50 gel (pH 7.5), over 32 hours (37 °C), were determined using 8 
UV-Vis spectroscopy. Nanoparticle size was measured by dynamic light scattering (DLS), and critical micelle 9 
concentration (CMC) by pyrene fluorescence. Polymer gel viscosity was examined via rheology, nanoparticle 10 
morphology investigated using scanning transmission electron microscopy (STEM), and the gel matrix observed 11 
using cryo-scanning electron microscopy (Cryo-SEM).  12 
Key Findings 13 
DPA50-MPC250-DPA50 copolymer (15 % w/v) formed a free-standing gel (pH 7.5) that controlled drug release 14 
relative to free drugs. The copolymer possessed a low CMC, nanoparticle size increased with copolymer 15 
concentration, and DLS data was consistent with STEM. The gel displayed thermostable viscosity at 16 
physiological temperatures, and the gel matrix was a nanostructured aggregation of smaller nanoparticles. 17 
Conclusions 18 
The DPA50-MPC250-DPA50 copolymer gel could be used as a drug delivery system to provide the controlled drug 19 
release of ketoprofen and spironolactone. 20 
Keywords 21 
DPA-MPC-DPA, pH sensitive, Nanoparticles, Polymer gel, Drug delivery system, Controlled release 22 
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Introduction  1 
Traditional drug formulations for parenteral and oral administrations, can experience challenges such as rapid, 2 
first pass, metabolism where the drug is metabolised quickly in the liver before reaching the blood circulation, 3 
resulting in low efficacy and high side effects. Nanotechnology has afforded the development of pharmaceutical 4 
strategies to produce therapeutics with improved metabolism, dissolution and clearance profiles, and in doing so, 5 
reduce side effects and increase the efficacy of medicines. For example, nanoparticles have important advantages 6 
such as the surface area per unit mass of nano-sized formulations being significantly improved, leading to 7 
increased dissolution rates, however, intravenously administered therapeutic agents can also target healthy cells 8 
and create  undesired side effects. 
[1]
 9 
An alternative strategy is available in the form of polymer gel biomaterials that can act as controlled release 10 
reservoirs, either at the site of localised therapeutic action, or as a depot for wider distribution in a controlled and 11 
extended mode, and thus reduce unwanted systemic effects. Recently there has been interest in stimuli-12 
responsive block copolymer hydrogels with temperature 
[2, 3]
 and pH-responsive sensitivity 
[4 - 6]
 for 13 
pharmaceutical applications. These have included triblock copolymers containing both hydrophilic and 14 
hydrophobic domains for the formation of nanoparticle micelle based gels for drug delivery system applications, 15 
[7 - 10]
 where formation of free-standing hydrogels is achieved by a polymeric nanostructure. 
[11]
 Examples of 16 
proposed applications include suppositories, 
[12]
 implants, 
[13]
 and transdermal patches, 
[14]
 to provide controlled 17 
drug release at a target site, with Poloxamer based hydrogels often described. 
[15 – 17]
 The principle advantage of 18 
triblock ABA copolymers, for example PEG-PLGA-PEG over diblock AB copolymers, for example PEG-19 
PLGA, being the ability of the triblock to form gels at a lower polymer concentration, 
[18]
 due to the B block 20 
forming bridges between the A blocks, 
[19]
 when in a solvent that is suitable for one of the blocks. 
[20] 21 
For a drug-eluting biomaterial to be fit for purpose it needs to be biocompatible, and ideally biomimetic, such 22 
that it avoids eliciting an immune response at the host site which may negatively affect the drug elution kinetics. 23 
One strategy to achieve this is to mimic cell membrane components, and thus copolymers utilising 24 
phosphorylcholine (PC) have been developed for biomedical applications, 
[21, 22]
 including those that form 25 
hydrogels. 
[23 – 25]
 An example of PC containing polymers are the poly(2-methacryloyloxyethyl 26 
phosphorylcholine)-b-poly(2-(diisopropylamino)ethyl methacrylate) (MPC-DPA) range of diblock copolymers 27 
that have been developed for nanoparticle suspension drug delivery applications. 
[26 - 28]
 The MPC component is 28 
biocompatible and able to resist protein adsorption and cell adhesion, 
[29 – 31]
 due to high levels of water binding, 29 
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[32]
 however, the MPC-DPA diblock copolymers do not form gels. 
[4]
 In contrast, development and investigation 1 
of DPA-MPC-DPA triblock copolymers has, to date, been limited to a small number of reports. 
[4, 33 – 35]
 2 
The triblock copolymer DPA50-MPC250-DPA50 contains an MPC core block to provide biocompatibility, 
[32]
 and 3 
has been shown to form gels at concentrations above 10 % w/v at pH 7.5, 
[4]
 where it was used as a model drug 4 
delivery system with dipyridamole. These pH sensitive polymers reversibly self-assemble when the pH of their 5 
local environment is raised, 
[26]
 which provides some advantages over chemically cross-linked hydrogels for 6 
biomedical applications. 
[2]
 For example, the in situ sol-gel transition is reliant upon physical-cross linking 
[36]
 7 
which also provides a delivery mechanism for controlling drug release, together with subsequent ease of rapid 8 
removal of the polymer if necessary via a simple pH reduction. 
[37]
 Whilst there could be widespread applications 9 
for these DPA-MPC-DPA copolymer gels,
 [12, 14, 38]
 there remains a number of physiochemical characteristics 10 
which may affect drug release profiles from these materials, including particle size, drug concentration, and 11 
possible material interactions, which require further elucidation. 12 
For this current study, contrasting hydrophilic and hydrophobic model drugs, ketoprofen and spironolactone, 13 
respectively, were chosen, based on their successful use in a PEG-PLGA-PEG polymer gel study. 
[39]
 Ketoprofen 14 
is antipyretic, anti-inflammatory, and analgesic, and spironolactone is a potassium sparing diuretic used as an 15 
antihypertensive drug and also to treat Oedema in congestive heart failure. 
[40]
 16 
The aims of this study were to determine the release profiles of ketoprofen and spironolactone from a pH-17 
responsive self-assembling nanostructured DPA50-MPC250-DPA50 triblock copolymer gel, and elucidate the 18 
underlying physiochemical properties of the gel. The novelty of this papers lies within the novel DPA-MPC-19 
DPA triblock copolymer, which to date has seen limited publication and research data dissemination, the 20 
underpinning novel data pertaining to the copolymer physicochemical characterisation and performance 21 
presented herein, and the novel application of the copolymer for controlled and extended drug release, in both 22 
singular and combined drug loaded configurations. As such, this paper reports for the first time novel data 23 
regarding controlled drug release from this copolymer gel biomaterial over a 32 hour period, together with gel 24 
viscosity at physiological temperatures, and reveals the underlying nanostructured architecture of the copolymer 25 
gel matrix. In doing so, it makes an important contribution to furthering the understanding of DPA-MPC-DPA 26 
triblock copolymers, and highlights the potential use of the copolymer gel for controlled drug delivery 27 
applications. 28 
 29 
Materials and methods 30 
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Materials 1 
The poly(2-(diisopropylamino)ethyl methacrylate)-b-poly(2-methacryloyloxyethyl phosphorylcholine)-b-poly(2-2 
(diisopropylamino)ethyl methacrylate) (DPA50-MPC250-DPA50) triblock copolymer was supplied by Prof Steven 3 
Armes (University of Sheffield, UK) having been synthesised by atom transfer radical polymerisation (ATRP), 4 
as detailed previously. 
[4]
 Hydrochloric acid (HCl), sodium hydroxide (NaOH), ketoprofen (keto) (98%), 5 
spironolactone (spiro) (97%), pyrene (99%), phosphotungstic acid (PTA), and Tween 20 were purchased from 6 
Sigma Aldrich, UK. Phosphate buffered saline (PBS), 12-14 kDa MWCO dialysis tubing, methanol, and 0.22 7 
µm syringe filters were purchased from Fisher Scientific, UK. Transmission electron microscopy (TEM) grids 8 
were purchased from Agar Scientific, UK.  9 
 10 
NMR and GPC polymer characterisation 11 
Block ratio composition and molecular weight of the received DPA50-MPC250-DPA50 copolymer were confirmed 12 
by 
1
H nuclear magnetic resonance spectroscopy (NMR) and gel permeation chromatography (GPC) using 13 
protocols detailed previously. 
[28]
 14 
 15 
DPA-MPC-DPA polymer solutions 16 
The DPA50-MPC250-DPA50 copolymer was dissolved in 0.1 M HCl, the pH raised with 3M NaOH, and the final 17 
volume adjusted with deionised water. Samples were prepared at 0.15 % w/v (1.5 mg ml
-1
), 1.5 % w/v (15 mg 18 
ml
-1
) and 15 % w/v (150 mg ml
-1
) at pH 2.0 and pH 7.5.  19 
 20 
Ketoprofen and spironolactone standard curves 21 
The lambda max (λ max) for keto and spiro was determined in release medium (RM), consisting of phosphate 22 
buffered saline (PBS) (pH 7.5) containing 0.2 % w/w Tween 20 
[39]
 using a Perkin Elmer Lambda 25 UV-Vis 23 
spectrophotometer. Standard curves for serial halving dilutions of keto and spiro, singularly and in combination, 24 
in RM, (100 µg ml
-1
) were then constructed. 25 
 26 
Ketoprofen and spironolactone free drug release 27 
Keto was dissolved in 0.1 M HCl, the pH adjusted to pH 7.5 with 3 M NaOH, and the volume adjusted with 28 
deionised water to give a test concentration of 10 mg ml
-1
. 
[39]
 Test sample volumes (2 ml) were transferred to 29 
12-14 kDa MWCO dialysis tubing, sealed, and placed in 10 ml of RM (pH 7.5) at 37 °C, with 100 rpm magnetic 30 
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bar stirring, to begin free drug release. Thermally equilibrated (37 °C) 10 ml volumes of RM were used to 1 
replace the RM at hourly time intervals. Keto concentration in the RM samples was determined at the λ max 2 
(260 nm) using the standard curve, and the cumulative release of free keto over 32 hours calculated. Spiro was 3 
prepared, and free drug release determined at the λ max (241 nm), as per keto, at a spiro test concentration of 2.5 4 
mg ml
-1
. 
[39]
 The free drug release over 32 hours for a combined sample of keto (10 mg ml
-1
) and spiro (2.5 mg
-1
) 5 
was also determined using the same methodology.  Samples were prepared and measured in triplicate. 6 
 7 
Ketoprofen and spironolactone controlled release from DPA-MPC-DPA gel 8 
Keto loaded copolymer gel was prepared by dissolving DPA50-MPC250-DPA50 and keto in 0.1 M HCl, adjusting 9 
the pH to pH 7.5 with 3 M NaOH, to induce copolymer gelation, then adjusting the volume with deionised water 10 
to produce a 15 % w/v copolymer gel (150 mg ml
-1
) containing keto at 10 mg ml
-1
. Test sample volumes (2 ml) 11 
were transferred to 12-14 kDa MWCO dialysis tubing, sealed, and placed in 10 ml of RM (pH 7.5) at 37 °C, 12 
with 100 rpm magnetic bar stirring, to begin drug release. Thermally equilibrated (37 °C) 10 ml volumes of RM 13 
were used to replace the RM at hourly time intervals. Keto concentration in the RM samples was determined at 14 
the λ max (260 nm) using the standard curve, and the controlled cumulative release of keto from the 15 % w/v 15 
copolymer gel over 32 hours calculated. Spiro in 15 % w/v copolymer gel was prepared, and controlled drug 16 
release determined at the λ max (241 nm), as per keto, at a spiro concentration of 2.5 mg ml-1. The controlled 17 
drug release over 32 hours for a combined sample of keto (10 mg ml
-1
) and spiro (2.5 mg ml
-1
) in 15 % w/v 18 
polymer gel was also determined using the same methodology.  Samples were prepared and measured in 19 
triplicate. 20 
 21 
Fourier transform infrared spectroscopy 22 
Fourier transform infrared spectroscopy (FTIR) was performed on dried samples using a Perkin Elmer Spectrum 23 
65 FT-IR spectrometer. All transmission spectra were obtained at ambient temperature by recording the average 24 
of 16 scans in the region between a wave number 4000 and 650 cm
-1
 with a resolution of 4 cm
-1
. 25 
 26 
Nanosystem characterisation 27 
The DPA50-MPC250-DPA50 nanosystems were assessed for particle size, polydispersity, critical micelle 28 
concentration (CMC), viscosity, and particle morphology, using dynamic light scattering (DLS), fluorescence 29 
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spectrophotometry, rheology, scanning transmission electron microscopy (STEM), and cryo-scanning electron 1 
microscopy (Cryo-SEM). 2 
 3 
Dynamic light scattering 4 
Particle size (Dh) and polydispersity (Pd) of 0.15 % w/v solution DPA50-MPC250-DPA50 copolymer nanoparticle 5 
systems, at pH 2.0 and pH 7.5, were measured at 25° C, with a Malvern Zetasizer Nano ZS90 instrument, using 6 
the DLS method detailed previously. 
[28]
 Samples were prepared and measured in triplicate. 7 
 8 
Critical micelle concentration 9 
The CMC of the 1.5 % w/v DPA50-MPC250-DPA50 copolymer nanosystem at pH 7.5 was determined via 10 
fluorescence spectrometry using pyrene as the probe. Serial halving dilutions (3 ml volumes) of the sample were 11 
prepared with PBS (pH 7.5), and pyrene (25 µg ml
-1
 in methanol) added (50 µl) to each. The pyrene fluorescence 12 
spectra was measured for each dilution using a Varian Eclipse Fluorescence spectrophotometer, at an excitation 13 
wavelength of 334 nm, with emission collected from 345 – 480 nm, using 10 nm excitation and 2.5 nm emission 14 
slits, 30 nm min
-1
 scan rate, and 0.5 nm data interval. 
[41]
 Samples were prepared and measured in triplicate. 15 
 16 
Rheology 17 
The viscosity of the DPA50-MPC250-DPA50 copolymer nanosystems (0.15, 1.5, and 15 % w/v) at pH 7.5 was 18 
determined with a HAAKE Rheostress rheometer, using 1 Pa oscillating shear stress across a 20 – 50 °C 19 
temperature range at 1.5 °C intervals. Samples were prepared and measured in triplicate. 20 
 21 
Scanning transmission electron microscopy 22 
Particle morphology of 0.15 and 1.5 % w/v DPA50-MPC250-DPA50 copolymer nanoparticle systems was 23 
investigated at pH 7.5, via STEM, using a Zeiss SIGMA field emission gun scanning electron microscope (FEG-24 
SEM) equipped with a Zeiss STEM detector. Working conditions used were; 20 kV accelerating voltage, 20 µm 25 
aperture, and 3 mm working distance. To prepare the STEM samples, 200 mesh Formvar coated copper TEM 26 
grids were plasma treated (5 watts) in a Polaron PT7150 plasma barrel etcher for 30 seconds, to improve surface 27 
wettability, 1 drop of sample applied to the TEM grid for 60 seconds, excess wicked way, 1 drop of filtered (0.22 28 
µm) 2 % w/v PTA (pH 7.5) applied to the TEM grid for 60 seconds, excess wicked away, and then air dried. 29 
 30 
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Cryo scanning electron microscopy 1 
The morphology of the 15 % w/v DPA50-MPC250-DPA50 copolymer nanoparticle system in gel form (pH 7.5), 2 
was examined via Cryo-SEM, using a Quorum Technologies PP3000T cryogenic sample preparation system and 3 
Zeiss SIGMA FEG-SEM, according to the method detailed previously. 
[28]
 4 
 5 
Data analysis 6 
Data are presented as Mean ± standard deviation (SD) of triplicate repeat experiments (n = 3). The FDA 7 
preferred model-independent similarity factor, f2, was calculated for comparing the cumulative release profiles 8 
where f2 > 50 indicates similarity, and f2 = 100 is considered identical.
 [42, 43]
  Model-dependant analysis of the 9 
release profiles was undertaken using zero order, first order, and Higuchi mathematical functions to determine 10 
the coefficient of determination R
2
 values, where R
2
 > was indicative of good fit, and the rate constants K0, K1, 11 
and KH respectively. 
[44, 45]
 Statistical significance of the cumulative release data was assessed using the non-12 
parametric, two-tail, Mann-Whitney U test (Minitab 16), comparing the gel loaded drug release profile curves 13 
against the free drug release profile curves 
[46, 47]
 where P < 0.05 was considered significant. 14 
 15 
Results and Discussion 16 
NMR and GPC polymer characterisation 17 
The composition of the DPA50-MPC250-DPA50 triblock copolymer was confirmed using 
1
H NMR and GPC, as 18 
shown in Figure 1 and Table 1. The 
1
H NMR data was consistent with previous reports, 
[4]
 whilst the GPC 19 
analysis, using an optimised organic GPC protocol, 
[28]
 improved the GPC to NMR data correlation. The results 20 
(Figure 1 and Table 1) indicated that the DPA50-MPC250-DPA50 copolymer was well defined, and of low 21 
polydispersity (1.01). 22 
 23 
DPA-MPC-DPA polymer solutions 24 
The DPA50-MPC250-DPA50 triblock copolymer aqueous solutions prepared (0.15, 1.5, and 15 % w/v) were fluid 25 
and free-flowing in acidic solution (pH 2). The pKa of DPA is circa pH 6, at which point it becomes 26 
deprotonated and hydrophobic 
[4]
, and diblock MPC-DPA copolymers are reported to form micelles between pH 27 
6 and pH 7 in solution 
[26]
. Therefore the DPA-MPC-DPA triblock copolymer is predicted to begin forming 28 
flower-like micelles across the same pH 6-7 range, with a resultant gel formation if the polymer w/v % is 29 
sufficient. When the pH was raised to pH 7.5, the 0.15 and 1.5 % w/v solutions remained free-flowing, whilst the 30 
 9 
 
15 % w/v solution formed a free-standing gel, as seen in Figure 2. This was consistent with previous reports, 
[4]
 1 
and attributed to the deprotonation of the DPA blocks resulting in micelle formation, and then subsequent 2 
interaction of the triblock chains to form the gel network observed at 15 % w/v concentration.  3 
 4 
Ketoprofen and spironolactone standard curves 5 
The λ max wavelengths for keto and spiro in RM were determined as 260 and 241 nm respectively, which were 6 
consistent with other reports. 
[39]
  Standard curves for these were constructed alone and in combination, as shown 7 
in Figure 3, with the coefficient of determination (R
2
) values for all of curves (Figure 3 a, b, c, d)  being 0.9996 8 
or greater, and thus of good linear fit. These curves were subsequently used to determine the keto and spiro drug 9 
release profiles. 10 
 11 
Ketoprofen and spironolactone individual release rates 12 
Initially, keto and spiro were tested individually, and Figure 4 displays the free drug release, together with 13 
controlled release from the 15 % w/v DPA50-MPC250-DPA50 triblock copolymer gel, at pH 7.5 in RM. The keto 14 
(10 mg ml
-1
) free drug release rate was rapid, with circa 82 % released after 1 hour, whilst in comparison, the 15 
DPA50-MPC250-DPA50 gel loaded keto displayed a decreased release rate of circa 58% at the 1 hour time point, a 16 
reduction of circa 24 %. The first 8 hours produced the greatest decrease in drug release, and controlled release 17 
of keto from the copolymer gel was maintained for the 32 hour experimental duration. The model-independent f2 18 
similarity value was calculated as 47, which was below the lower limit of the 50 to 100 similarity value range, 19 
and therefore the profiles were not considered similar. The Mann-Whitney U test indicated a statistically 20 
significant difference between the keto release profile curve from the copolymer gel (Median = 92.43) and the 21 
free keto release (Median = 97.41), W = 3435, p = 0.0025. The spiro (2.5 mg ml
-1
) release rate was also 22 
decreased when loaded into the copolymer gel compared to the free drug, with a decrease in release rate from 23 
circa 16 % down to circa 10 % at the first hour, a reduction of circa 6 %, and again controlled release from the 24 
copolymer gel was maintained for the 32 hour experimental duration. The f2 similarity value was calculated as 25 
25, and therefore the profiles were not considered similar. The Mann-Whitney U test indicated a statistically 26 
significant difference between the spiro release profile from the copolymer gel (Median = 32.50) and the free 27 
spiro release (Median = 42.41), W = 3335, p = 0.0161. The difference between the keto and spiro release rates 28 
being primarily due to the hydrophilic nature of keto versus the hydrophobic nature of spiro. 
[39, 40]
 Indeed, keto 29 
has a carboxyl group which at pH 7.5 becomes ionized and hydrophilic, 
[39]
 whilst in contrast spiro is 30 
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hydrophobic, and thus the water solubility of keto has been reported as circa 135 mg ml
-1
 at pH 6, whereas sprio 1 
is considered insoluble in water. 
[39, 48]
 Therefore adding Tween 20 to the RM was required to improve the 2 
solubility of the drugs, in particular spiro, as the solubility of spiro in RM has been reported as 0.12 mg ml
-1
. 
[39]
 3 
Additionally, to ensure release of the drugs through the dialysis membrane a 12-14 kDa MWCO was chosen, 4 
which was greater than the molecular weights of spiro (0.42 kDa) and keto (0.25 kDa), and also lower than 5 
molecular weight (95 kDa) of the DPA50-MPC250-DPA50 copolymer to ensure it was retained within the 6 
membrane. As stated, the release medium used for the dialysis experimental work included Tween 20 at 0.2 % 7 
w/v, which has been shown to be effective for use in spiro and keto dialysis release models 
[39]
, and no 8 
precipitation of drugs was observed.  9 
The difference in hydrophobicity between keto and spiro will have resulted in the drugs partitioning to different 10 
domains within the micelle based copolymer hydrogel, and thus the differing release profiles observed, which 11 
were consistent with previous keto and spiro data. 
[39] 
The model-dependant analysis of the keto, with and 12 
without gel, release data (Table 2) over the 0 – 32 hour time period indicated that zero order was not a good fit, 13 
with coefficient of determination R
2
 values < 0.35 evident. First order was a closer fit for 0 - 32 hours, with R
2
 14 
values > 0.72, suggesting a concentration gradient related release of the hydrophilic keto. However it was also 15 
noted that the release rate was greater, and the slope steeper, within the first 0 – 8 hours relative to the final 24 – 16 
32 hours (Figure 4), and thus possibly a biphasic release profile, comprising first order for 0 – 8 hours (R2 > 17 
0.84) and zero order for 24 – 32 hours (R2 > 0.96). There was also some evidence for Higuchi model release (R2 18 
= 0.87) for the gel loaded keto sample during the 0 – 8 hour period, which would be consistent with the gel 19 
providing controlled diffusion and release of the keto. Comparison of the 0 – 8 hours first order rate constant 20 
(K1) values (Table 2) indicated that gel loaded keto (K1 = -0.124) was released at a slower rate than the free keto 21 
(K1 = -0.189). The model-dependant analysis of the spiro, with and without gel, release data (Table 2) was 22 
similar to the keto release, with the data again suggesting a biphasic release of first order from 0 – 8 hours (R2 > 23 
0.88) followed by zero order for the 24 – 32 hour period (R2 > 0.99), and also, again, possibly Higuchi release 24 
(R
2
 > 0.91) due to gel loading and the hydrophobicity of spiro producing a matrix diffusion-like release profile. 25 
It has been reported previously that keto and spiro release from polymer gels may indeed fit first order and 26 
Higuchi models. 
[39]
 Comparison of the 0 – 8 hours first order rate constant (K1) values (Table 2) indicated that 27 
gel loaded spiro (K1 = -0.019) was released at a slower rate than the free spiro (K1 = -0.024).  28 
In summary, sustained and controlled drug release from the DPA50-MPC250-DPA50 15 % w/v copolymer gel was 29 
achieved for keto and spiro relative to the free drugs. Whilst this current study investigated drug release at pH 30 
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7.5, and achieved reduced and controlled drug release profiles, reductions in the local pH environment could 1 
affect the profiles. If the pH was lowered the micelle based gel would dissociate and dissemble, which would 2 
result in a faster release of the loaded drugs, as reported previously 
[4]
 for dipyridamole release. Thus, given the 3 
pH responsive nature of the DPA-MPC-DPA polymer, 
[4]
 it also offers the possibility to react, and release drugs, 4 
to changes in localised pH, for example biofilm, 
[49]
 and tissue necrosis, 
[50]
 associated acidification, and thus 5 
respond actively and autonomously to changing therapeutic needs.  6 
 7 
Ketoprofen and spironolactone combined release rates 8 
Subsequently, the release rates for combinations of keto and spiro, as free drugs, and loaded into 15 % w/v 9 
DPA50-MPC250-DPA50 copolymer gels, were determined. It can be seen from Figure 5 and Table 3 that the 10 
combination release rate was reduced for the gel loaded drugs in comparison to the free drugs. Loading the keto 11 
and spiro together, in combination, in the copolymer gel produced a large decrease in keto release, from circa 71 12 
% down to circa 32%, a reduction of circa 39 % at 1 hour, and also an overall decrease and prolonged controlled 13 
release for spiro over the 32 hour experimental time course. The model-independent f2 similarity value for keto 14 
in combination with spiro was calculated as -13, and therefore the profiles were not considered similar. The 15 
Mann-Whitney U test indicated a statistically significant difference between the keto release profile from the 16 
copolymer with spiro gel (Median = 45.79) and the free keto with spiro release (Median = 97.91), W = 4370, p < 17 
0.001. The f2 similarity value for spiro in combination with keto was calculated as -4, and therefore the profiles 18 
were not considered similar. The Mann-Whitney U test indicated a statistically significant difference between the 19 
spiro release profile from the copolymer with keto gel (Median = 26.14) and the free spiro with keto release 20 
(Median = 57.94), W = 4109, p < 0.001.   21 
Model-dependant analysis of the keto in combination with spiro, with and without gel, release data (Table 2) 22 
indicated that zero order was not an appropriate model (R
2
 < 0.40) for the 0 – 32 hour period, and that the best fit 23 
for the profiles were first order during 0 – 8 hours (R2 > 0.75) followed by zero order for 24 – 32 hours (R2 > 24 
0.96), and thus further evidence of biphasic release. The data (Table 2) also suggested, again, the possibility of 25 
Higuchi, matrix diffusion, release for the gel loaded sample (R
2
 = 0.90) from 0 – 8 hours. Comparison of the 0 – 26 
8 hrs first order rate constant (K1) values (Table 2) indicated that gel loaded keto in combination with spiro (K1 = 27 
-0.035) was released at a slower rate than the free keto in combination with spiro (K1 = -0.177).  28 
The spiro in combination with keto, without gel, also appeared to display biphasic release, with either first order 29 
(R
2
 = 0.92) or Higuchi release (R
2
 = 0.96), 0 – 8 hours, followed by zero order (R2 = 0.99) over 24 – 32 hours. 30 
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Interestingly, the R
2
 data for spiro in combination with keto, with gel loading, suggested that this sample 1 
underwent Higuchi release (R
2
 = 0.88) followed by zero order (R
2
 = 0.83) for the 0 – 8 and 24 – 32 hour periods 2 
respectively, possibly due to the combined effects of spiro hydrophobicity, material interactions, and gel loading, 3 
to create matrix diffusion-like release conditions. Comparison of the 0 – 8 hours first order rate constant (K1) 4 
values (Table 2) indicated that gel loaded spiro in combination with keto (K1 = -0.014) was released at a slower 5 
rate than the free spiro in combination with keto (K1 = -0.042).  6 
It is recognised that in some instances and applications, it may be expected or desirable, to control and achieve a 7 
full 100 % drug release over a set and distinct period of time. However, in the case of novel applications of 8 
newly emerging materials such as DPA-MPC-DPA, where “model” drugs are used for proof of concept, a set 9 
time is less relevant, as it may be the case that the controlled release is extended beyond the experimental period, 10 
as was observed with the 32 hours duration of this study. In doing so, the study and novel data provided an 11 
important insight into the potential for the material to be utilised as a reservoir for long-term, slow, zero order, 12 
drug release applications, for which future work is required to elucidate this further. For example, the elution test 13 
parameters can control the release profile, if more Tween 20 surfactant had been added to the RM, or a larger 14 
RM volume used, then the release profile would change, and, moreover, if lower amounts of drugs had been 15 
added to the gel, the cumulative % amount released would have been greater for the same 32 hour time period.  16 
Regarding the slow release observed, the hydrophobic spiro would have partitioned into the flower-like micelle 17 
cores of the copolymer gel, due to the hydrophobic effect, whilst the more hydrophilic keto would have 18 
undergone molecular dissolution into the aqueous phase of the hydrated gel. The FTIR analysis suggested that 19 
there were no direct material interactions involved in controlling drug release; therefore the spiro in the micelle 20 
cores may have caused micelle driven gel constriction and restricted keto release, whilst the keto in the aqueous 21 
phase may have retarded the spiro release. The release profile slopes of the gel loaded drugs had indeed become 22 
shallow at 32 hours, but had not stopped, and over an extended period of time, which could be tuned and 23 
optimised to specific application needs, drug release would reach completion. 24 
In summary, whilst the combined drug release profiles (Figure 5) differed from the individual drug release 25 
profiles (Figure 4), as summarised for the 1, 8, 24, and 32 hour time points in Table 3 and illustrated by the 26 
differing rate constant values in Table 2, the controlled drug release from the DPA50-MPC250-DPA50 15 % w/v 27 
copolymer gel was again achieved relative to the free drugs. 28 
 29 
Fourier transform infrared spectroscopy 30 
 13 
 
It was noted from Figures 4 and 5, and Table 3 that the drug release profiles for keto and spiro altered when 1 
tested in combination versus when tested individually, and keto has been reported to undergo hydrogen bonding 2 
physical interactions with PLGA. 
[51]
 To explore this, FTIR was utilised to investigate possible polymer-drug and 3 
drug-drug interactions. However, in this instance, there was no evidence of sample material interactions, as there 4 
were no shifts in the characteristic absorbance peaks detectable in FTIR spectra, which are displayed in Figure 6. 5 
It is possible that the presence of the more hydrophobic spiro within the micelle cores caused the nanostructed 6 
gel to constrict, and thus reduced the keto release. Inversely, the more hydrophilic keto may have saturated the 7 
aqueous component of the gel, and thus retarded spiro release. The alterations in drug release profiles observed 8 
therefore require further investigation to be fully understood, and it has been suggested that inclusion of 9 
hydrophilic additives with hydrophobic drugs can indeed improve their water solubility. 
[52]
  10 
 11 
Dynamic light scattering 12 
The DLS particle sizing data for DPA50-MPC250-DPA50 (0.15 % w/v) is shown in Table 4, and indicated that at 13 
pH 2.0 the particle size was circa 16 nm, which was consistent with unimer size, whilst at pH 7.5 the average 14 
particle size was circa 63 nm, which was indicative of micelle formation. 
[26]
 The polydispersity (Pd) of the 15 
samples was also reduced at pH 7.5, compared to pH 2.0, suggesting further the formation of uniform nano-16 
structured morphologies. The DLS particle size data was in good agreement with the STEM imaging data. 17 
 18 
Critical micelle concentration 19 
The CMC of the DPA50-MPC250-DPA50 (1.5 % w/v) copolymer solutions (pH 7.5) was determined by pyrene 20 
fluorescence spectroscopy. The convention for determining CMC is to identify the points of inflection associated 21 
with spectral shifts in the pyrene fluorescence ratio for peaks 1 vs 3, 
[41, 53]
 resulting from changes in nanoparticle 22 
morphology. The morphological changes and spectral shifts are associated with the concentration dependant 23 
formation of micelles. 
[54 – 57]
 This can be seen in Figure 7, where the shift from unimer to micelle began at circa 24 
0.004 mg ml
-1
 (CMC
1
), and was complete by circa 0.469 mg ml
-1
 (CMC
3
). Single values are often cited when 25 
reporting CMC data, however CMC can also be viewed as a concentration range, 
[58]
 with a start (CMC
1
), mid 26 
(CMC
2
), and end point (CMC
3
), as highlighted in Figure 7, and thus herein the CMC range data are presented in 27 
Table 4. 28 
With regard to the DPA-MPC-DPA copolymer, the hydrophilic MPC blocks surround the hydrophobic DPA 29 
blocks, and the DPA core of the micelle solubilizes the hydrophobic pyrene such that it acts as a precise probe 30 
 14 
 
for the micelle formation process. 
[59 - 62]
 The CMC is an important parameter for improving dilution stability of 1 
the gel, decreasing the CMC improves micelle stability, and thus drug release is slower. 
[10] 2 
 3 
Rheology 4 
The viscosity (Pa.s) against temperature (20 – 50 °C) was determined for the 15, 1.5, and 0.15 % w/v solutions 5 
(pH 7.5) of DPA50-MPC250-DPA50 as shown in Figure 8. The rheological data was consistent with the 15 % w/v 6 
solution having formed a free-standing gel, as the viscosity ranged from circa 26 Pa.s at 20 °C to circa 43 Pa.s at 7 
50 °C, suggesting some evidence of thermal-induced gel thickening from circa 40 – 50 °C. At physiological 8 
temperatures (36.5 – 37.5 °C) viscosity was circa 31 Pa.s, which was an improvement upon reports of  other PC 9 
containing triblock copolymer gel systems, such as PPO-PMPC-PNIPAM, that had low viscosity (circa 1 Pa.s) 10 
across the same temperature range. 
[36]
 In contrast, the viscosity of the 1.5 and 0.15 % w/v solutions remained 11 
stable at, and less than, 0.01 Pa.s across the tested temperature range, which was consistent with the free-flowing 12 
solutions observed. In this study the gel was tested at 15 % w/v, and temperature induced gel transitions were 13 
observed between 40 – 50 °C. It has previously been reported that the gel consistency, and free-standing ability, 14 
increases as the % w/v increases 
[4]
. Therefore it is possible that DPA-MPC-DPA gels prepared at much higher 15 
w/v % concentrations may indeed display a greater level of thermo-stability, and thus reduced level of sol-gel 16 
transitions at higher temperatures. In summary, the 15 % w/v DPA50-MPC250-DPA50 copolymer gel displayed 17 
stable viscosity at the physiological temperatures required for clinical application. 18 
 19 
Scanning transmission electron microscopy 20 
STEM imaging was conducted to investigate nanoparticle self-assembly, and morphology, of DPA50-MPC250-21 
DPA50 copolymer at 0.15 and 1.5 % w/v solutions (pH 7.5). The 15 % w/v sample was in gel form, and not 22 
suitable for STEM analysis. As shown in Figure 9a and b, the 0.15 % w/v sample formed relatively uniform 23 
nanoparticles of circa 60 nm diameter, which was in close agreement with the DLS data (Table 4). The 1.5 % 24 
w/v sample formed larger flower-like particle aggregates of the smaller (60 nm) particles, which were circa 600 25 
nm diameter, as seen in Figure 9c and d. These data supported the proposed, concentration dependant particle 26 
interaction, process responsible for driving the nanostructured gel formation. 
[4]
 Indeed, particle morphology 27 
changes have been reported previously for MPC-DPA diblock copolymers, 
[63, 64]
 and also alternative polymers, 28 
such as G54-H140 diblock copolymer,
 [11]
 where free-flowing spherical micelle solutions were reported at low 29 
concentration and free-standing wormlike micelle gels at high concentration. 
 30 
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 1 
Cryo scanning electron microscopy 2 
The DPA50-MPC250-DPA50 bulk material gel matrix, and nano-morphology, of the 15 % w/v copolymer gel 3 
sample (pH 7.5) was examined using Cryo-SEM as seen in Figure 10. The results indicated that the bulk gel 4 
material consisted of an interconnected copolymer network matrix (Figure 10a), which was constructed from an 5 
aggregation of smaller nanoparticles of circa 60 nm diameter (Figure 10b). The triblock nanoparticle size and 6 
morphology was similar to previous reports of MPC-DPA diblock nanoparticles. 
[26 - 28, 63]
 The data were 7 
consistent with the DLS particle sizing (Table 4) and STEM imaging data (Figure 9), and illustrated further the 8 
concentration driven particle aggregation, at pH 7.5, proposed for the formation of the DPA50-MPC250-DPA50 9 
nanostructured gel observed (Figure 10).  10 
 11 
Conclusions  12 
In conclusion, this paper presents the first report of keto and spiro loading and controlled release from the PC 13 
containing biomaterial triblock copolymer DPA50-MPC250-DPA50 gel system. The study contributed novel data 14 
to, and expanded upon, the currently limited knowledge of DPA-MPC-DPA, including an optimised GPC 15 
analysis, which provided an improved GPC to NMR correlation. The data successfully demonstrated controlled 16 
release of contrasting hydrophobic and hydrophilic drugs from a 15 % w/v gel over a 32 hour period, the 17 
potential to modulate release further by combining drugs, and the excellent stability of the gel in the form of 18 
physiologically thermostable viscosity and a low CMC. Investigation of the gel system architecture using STEM 19 
and Cryo-SEM revealed the concentration and pH driven nanoparticle aggregation, which resulted in formation 20 
of the nanostructured copolymer gel matrix. These novel data make an important contribution to elucidating the 21 
potential for pharmaceutical applications of DPA-MPC-DPA, and demonstrated the possibility of combinational 22 
drug therapy, which could provide treatment for several conditions from a single application. 23 
 24 
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Tables 1 
 2 
Table 1 Molecular weight (Mn and Mw) and polydispersity (Mw/Mn) of DPA50-MPC250-DPA50 triblock 3 
copolymer determined via 
1
H NMR and organic GPC 4 
 5 
DPA50-MPC250-DPA50 Mn Mw Mw/Mn 
Target 
(g.mol
-1
) 
95150 - - 
1
H NMR 
 
95150 - - 
GPC 89030 89480 1.01 
 6 
 7 
Table 2 Model-dependant analysis of the keto and spiro release profiles, displaying the coefficient of 8 
determination R
2
 values, where R
2
 > was indicative of good fit, together with the zero order (K0), first order (K1), 9 
and Higuchi (KH) rate constants (K) 10 
 11 
  
 
Zero order 
K0 rate constant 
 
 
First order 
K1 rate constant 
 
 
Higuchi 
KH rate constant 
 
 
Time 
(hours) 
0-32 0-8 24-32 0-32 0-8 24-32 0-32 0-8 24-32 
Keto 
R
2
 0.189 0.420 0.999 0.880 0.844 0.899 0.342 0.701 0.998 
K 0.799 7.551 0.045 -0.066 -0.189 -0.112 7.121 29.732 0.479 
Keto + gel 
R
2
 0.343 0.615 0.963 0.724 0.898 0.967 0.529 0.867 0.968 
K 1.070 8.438 0.053 -0.026 -0.124 -0.005 8.812 30.521 0.558 
Spiro 
R
2
 0.771 0.838 0.995 0.855 0.886 0.997 0.908 0.984 0.997 
K 1.023 4.252 0.689 -0.007 -0.024 -0.006 7.357 14.048 7.266 
Spiro + gel 
R
2
 0.860 0.907 0.991 0.912 0.936 0.991 0.964 0.996 0.990 
K 1.033 3.545 0.611 -0.007 -0.019 -0.005 7.245 11.320 6.447 
Keto (+ spiro) 
R
2
 0.232 0.489 0.962 0.866 0.813 0.975 0.399 0.768 0.966 
K 0.900 8.131 0.013 -0.068 -0.177 -0.032 7.818 31.060 0.136 
Keto (+ spiro) 
+ gel 
R
2
 0.395 0.665 0.994 0.495 0.757 0.994 0.585 0.900 0.995 
K 0.706 5.227 0.069 -0.005 -0.035 -0.001 5.629 18.539 0.724 
Spiro (+ keto) 
R
2
 0.717 0.860 0.996 0.849 0.919 0.996 0.865 0.962 0.996 
K 1.356 6.423 0.642 -0.012 -0.042 -0.008 9.871 20.707 6.778 
Spiro (+ keto) 
+ gel 
R
2
 0.411 0.635 0.828 0.457 0.675 0.828 0.600 0.880 0.829 
K 0.387 2.705 0.010 -0.002 -0.014 -0.001 3.096 19.714 0.109 
  12 
   13 
 14 
 15 
 23 
 
    1 
Table 3 Cumulative release (%) data at the 1, 8, 24, and 32 hour time points, illustrating the effects of gel 2 
loading, and drug-drug and polymer-drug interactions, upon drug release (Mean ± SD, n = 3) 3 
   4 
 
Cumulative release (%) 
Time point 1 hour 8 hours 24 hours 32 hours 
keto 82.4 (± 2.8) 98.5 (± 0.3) 99.6 (± 0.7) 100.0 (± 0.4) 
Keto + gel 57.9 (± 8.9) 92.1 (± 0.7) 94.8 (± 2.1) 95.3 (± 0.2) 
Keto (+ spiro) 70.5 (± 3.3) 97.3 (± 0.3) 99.8 (± 0.7) 99.8 (± 0.8) 
Keto (+ spiro) + gel 31.6 (± 11.3) 54.7 (± 0.2) 56.9 (± 0.5) 57.4 (± 0.3) 
Spiro 16.0 (± 2.7) 39.1 (± 0.5) 47.3 (± 1.5) 52.9 (± 0.2) 
Spiro + gel 9.5 (± 3.5) 31.0 (± 1.2) 41.5 (± 1.4) 46.0 (± 0.4) 
Spiro (+ keto) 18.1 (± 6.9) 54.2 (± 0.7) 63.6 (±0.6) 69.0 (± 0.1) 
Spiro (+ keto) + gel 11.5 (± 1.5) 29.2 (± 0.1) 31.0 (± 0.9) 31.1 (± 0.2) 
 5 
 6 
Table 4 Particle size (Dh), polydispersity (Pd), and critical micelle concentration (CMC) of DPA50-MPC250-7 
DPA50 copolymer solutions (
a
0.15 % and 
b
1.5 % w/v) determined via DLS and pyrene fluorescence 8 
spectroscopy. (Mean ± SD, n = 3) 9 
  10 
DPA50-MPC250-DPA50 Dh 
(nm) 
a
 
Pd 
a
 CMC
1
 
(mg ml
-1
) 
b
 
CMC
2
 
(mg ml
-1
) 
b
 
CMC
3 
(mg ml
-1
) 
b
 
pH 2.0 16.6 (± 6.2) 0.536 (± 0.026) - - - 
pH 7.5 
 
63.0 (± 6.1) 0.257 (±0.013) 0.004 (± 0.055) 0.043 (± 0.021) 0.469 (± 0.011) 
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Figures 1 
 2 
Figure 1 
1
H NMR spectra (a) and GPC elution profile (b) of DPA50-MPC250-DPA50 triblock copolymer 3 
 4 
Figure 2 DPA50-MPC250-DPA50 15 % w/v copolymer, illustrating the free-flowing solution at pH 2 (a) versus 5 
the free-standing gel formed at pH7.5 (b)  6 
 7 
 8 
 9 
 25 
 
 1 
 2 
Figure 3 Standard curves of keto in RM (a), spiro in RM (b), keto in RM + spiro (c), and spiro in RM + keto (d) 3 
(Mean ± SD, n = 3) 4 
 5 
 6 
 7 
 8 
 26 
 
 1 
Figure 4 Individual cumulative drug release profiles of keto and spiro, in free solution, and from 15 % w/v 2 
DPA50-MPC250-DPA50 copolymer gel, in RM (pH 7.5) at 37 °C  (Mean ± SD, n = 3) 3 
 4 
 5 
Figure 5 Combined cumulative drug release profiles of keto(+spiro) and spiro(+keto), in free solution, and from 6 
15 % w/v DPA50-MPC250-DPA50 copolymer gel, in RM (pH 7.5) at 37 °C  (Mean ± SD, n = 3) 7 
 8 
 9 
Figure 6 FTIR spectra of (a) copolymer, (b) keto, (c) spiro, (d) copolymer + keto, (e) copolymer + spiro, (f) keto 10 
+ spiro, (g) copolymer + keto + spiro 11 
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 13 
 14 
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 27 
 
 1 
Figure 7 Critical micelle concentration of DPA50-MPC250-DPA50 at pH 7.5 determined by pyrene fluorescence 2 
spectrometry, indicating CMC
1
, CMC
2
, and CMC
3
 (Mean ± SD, n = 3) 3 
 4 
 5 
Figure 8 Temperature dependent (20 – 50 °C) viscosity (Pa.s) at 1 Pa oscillating stress, of 15, 1.5, and 0.15 % 6 
w/v DPA50-MPC250-DPA50 copolymer solutions (pH 7.5). (Mean ± SD, n = 3) 7 
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 1 
 2 
Figure 9 STEM images of 0.15 (a & b) and 1.5 (c & d) % w/v DPA50-MPC250-DPA50 copolymer solutions (pH 3 
7.5), displaying wide area views of the polymer nanoparticles, and zoomed areas to highlight nanoparticle size 4 
and morphology. Scale bars = 600 nm and 100 nm for wide and zoom respectively. 5 
 6 
 29 
 
 1 
 2 
Figure 10 Cryo-SEM images of 15 % w/v DPA50-MPC250-DPA50 copolymer solution (pH 7.5), displaying a 3 
wide area view of the polymer gel matrix (a), and a zoomed area highlighting the nanostructured composition of 4 
the gel material (b). Scale bars = 4 µm and 400 nm for wide and zoom respectively. 5 
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